Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Qing Deng, Guangchun Han, Nahum Puebla‐Osorio, +27

Nature Medicine

Lymphoid NeoplasiaRadiation OncologyCell TherapyCancer ImmunosurveillanceMedicine +8

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy

Anthony T. Tan, Ninghan Yang, Thinesh Lee Krishnamoorthy, +18

Gastroenterology

Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma

Jing Cui, Qi Zhang, Qi Song, +14

Neuro-Oncology

Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer

Jiang-Chuan He, Zhiwei Zhang, Saiqun Lv, +8

Cellular Immunology

Cell TherapyPancreatic CancerMedicineImmunologyPiggybac Transposon System +5

Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer

Jiannan Chen, Jianhua Hu, Lili Gu, +16

Cancer Immunology Immunotherapy

ImmunologyTherapeutic EfficacyAnti-mesothelin Car-t ImmunotherapyBiological TherapyImmunotherapy +2

Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma

Lin Fang, Weiping Tian, Chen Zhang, +5

Pharmacological Research

ImmunologyImmune RegulationImmunologic MechanismCd4 T Cell ResponsesImmune System +19

Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma

Chen Zhang, Lin Fang, Xueyan Wang, +5

Molecular Therapy — Oncolytics

Oncolytic Adenovirus-mediated ExpressionImmunologyRenal Cell CarcinomaTumor TargetingCancer Treatment +4

Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).

Juan Du, Weijun Fu, Hua Jiang, +16

Journal of Clinical Oncology

Cell TherapyMedian DurationImmunologyTransplantation MedicineImmunodominance +21

Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial

Fan Yang, Xiaofang Zheng, Sarene Koh, +12

Hepatology International

T Cell TherapyTransplantationHepatologyViral HepatitisMedicine +12

Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability

Jianghui Tang, Jianpeng Sheng, Qi Zhang, +7

Journal for ImmunoTherapy of Cancer